Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre.

Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Abstract Text:

Rohan Bhagwandeen,Anna Woo,John Ross,E Douglas Wigle,Harry Rakowski,Jennifer Kwinter,Maria J Eriksson,Leonard Schwartz,

BACKGROUND: Septal ethanol ablation (SEA) is a relatively new interventional nonsurgical treatment for patients with hypertrophic obstructive cardiomyopathy (HOCM). This procedure involves targeted infarction of the basal interventricular septum to reduce left ventricular outflow tract (LVOT) obstruction. OBJECTIVES: To describe the experience with this technique in a large tertiary care centre. METHODS AND RESULTS: Since 1998, 40 HOCM patients with disabling symptoms refractory to medical treatment have undergone SEA. Procedural success was 88% (35 of 40 patients). The LVOT gradient decreased from 86+/-38 mmHg to 16+/-16 mmHg. There were two major complications: one patient died of respiratory failure at 30 days following SEA, and one patient developed a major coronary dissection during the procedure and required emergency myectomy and coronary bypass surgery. There were two late failures (6% of initially successful cases). In both patients, the LVOT gradient and symptoms reappeared some months after the procedure and further interventions were required. In the remaining patients, the gradient continued to decrease to one year; 86% were asymptomatic or have mild symptoms compared with 94% with severe symptoms before SEA. Septal thickness decreased from 20.8+/-2.9 mm to 13.2+/-3.3 mm (P<0.001) at the site of the targeted septal infarct. CONCLUSION: SEA is a feasible option for suitable patients with HOCM.

Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Publishing Authors By Initials

R Bhagwandeen,A Woo,J Ross,ED Wigle,H Rakowski,J Kwinter,MJ Eriksson,L Schwartz,

For similar cardiovascular diseases: heart diseases: ventricular outflow obstruction research abstracts see: cardiovascular diseases: heart diseases: ventricular outflow obstruction research

PUBMED ID PMID:

MEDLINE DATE:

Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Canadian journal of cardiology

VOLUME: 19

Page Numbers: 912-7

Journal Abbreviation:

ISSN: 1916-7075

DAY: 3

MONTH: Jul

YEAR: 2003

Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8510280

Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Keywords Mesh Terms:

KEYWORDS: Ventricular Outflow Obstruction

MESH TERMS: ultrasonography

Chemical & Substance for Abstract: Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Information

Substance Name: Creatine Kinase

Registry Number: EC 2.7.3.2

Grant and Affiliation Information for Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre.

AFFILIATION: Toronto General Hospital, Toronto, Canada.

Country: Canada

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Can J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre Related Publications

• A dominant-negative p65 PAK peptide inhibits angiogenesis.
• After the war on terrorism, an attack on antibiotic resistance.
• Antiphase oscillation of the left and right suprachiasmatic nuclei.
• Changes in systolic blood pressure associated with lead in blood and bone.
• EDITORIAL: Globalization of Pediatrics.
• EDITORIAL:: Preparing for Future Amazement.
• Editorial.
• Editorial.
• Evaluation of 2 novel approaches for assessing the ability of demineralized freeze-dried bone allograft to induce new bone formation.
• Evidence for a coupling of synthesis and export of an outer membrane protein in Escherichia coli.
• Expression of chick Tbx-2, Tbx-3, and Tbx-5 genes during early heart development: evidence for BMP2 induction of Tbx2.
• In vivo DTI evaluation of white matter tracts in rat spinal cord.
• Integrative capacity of the caudal brainstem in the control of food intake.
• Lipid-lowering pharmacoeconomic studies. Reactor panel and open forum.
• MR Imaging and Epilepsy-3T or not 3T? That Is the Question.
• Monoclonal antibodies reveal lamB antigenic determinants on both faces of the Escherichia coli outer membrane.
• Monoclonal antibody as a probe for structure and function of an Escherichia coli outer membrane protein.
• Mutations that alter the transport function of the LamB protein in Escherichia coli.
• Nonadiabatic molecular dynamics simulations of correlated electrons in solution. 1. Full configuration interaction (CI) excited-state relaxation dynamics of hydrated dielectrons.
• Occupational health in Brazil.
• Phage lambda receptor (lamB protein) in Escherichia coli.
• Potential of porous poly-D,L-lactide-co-glycolide particles as a carrier for recombinant human bone morphogenetic protein-2 during osteoinduction in vivo.
• Recombinant bone morphogenetic protein (BMP)-2 regulates costochondral growth plate chondrocytes and induces expression of BMP-2 and BMP-4 in a cell maturation-dependent manner.
• Reconsidering the early steps of protein secretion.
• Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation.
• The ISPOR Lipid Conference: Pharmacoeconomics and Outcomes Modeling Issues.
• The Suprachiasmatic Nucleus is a Functionally Heterogeneous Timekeeping Organ.
• Transition path sampling study of classical rate-promoting vibrations.
• Using Per gene expression to search for photoperiodic oscillators in the hamster suprachiasmatic nucleus.
• p21-activated kinase regulates endothelial permeability through modulation of contractility.